 |
|
|
| |
The socio-economic burden of NASH in Europe and the United States: the GAIN study
|
| |
| |
- High Resource Use & Medical Costs Per Patient
- Indirect Costs to Patients & Caregivers, Productivity Losses Dwarf the Medical Costs....."Costs to Society for an untreated NASH population"
Presented by Jamie O'Hara
A retrospective and cross-sectional research study
Sponsorship received from
Novo Nordisk & Gilead
Tom Russell, Senior Consultant, HCD Economics
Rosa Willock, Project Manager , HCD Economics
Leo Ruiz, Senior Economist, HCD Economics
George Morgan, Health Economist, HCD Economics
Bethany Franks, RWE researcher, HCD Economics
Jamie O'Hara, CEO, HCD Economics
Reported by Jules Levin
EASL 2019
April 10-14 Vienna
|
| |
|
|
|
|
|
